Skip to main content

Amarin Corporation Plc (AMRN)

NASDAQ: AMRN · IEX Real-Time Price · USD
5.43
+0.03 (0.56%)
After-hours:Sep 24, 2021 7:33 PM EDT
5.40
-0.04 (-0.74%)
At close: Sep 24, 4:00 PM
Market Cap2.13B
Revenue (ttm)620.41M
Net Income (ttm)4.32M
Shares Out395.30M
EPS (ttm)0.01
PE Ratio540.00
Forward PE500.00
Dividendn/a
Ex-Dividend Daten/a
Volume2,763,392
Open5.40
Previous Close5.44
Day's Range5.33 - 5.52
52-Week Range3.58 - 9.25
Beta2.24
AnalystsBuy
Price Target10.75 (+99.1%)
Est. Earnings DateNov 4, 2021

About AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commerciali...

IndustryBiotechnology
IPO DateApr 1, 1993
CEOJoseph Zakrzewski
Employees1,000
Stock ExchangeNASDAQ
Ticker SymbolAMRN
Full Company Profile

Financial Performance

In 2020, Amarin's revenue was $614.06 million, an increase of 42.89% compared to the previous year's $429.76 million. Losses were -$18.00 million, -20.51% less than in 2019.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for Amarin stock is "Buy." The 12-month stock price forecast is 10.75, which is an increase of 99.07% from the latest price.

Price Target
$10.75
(99.07% upside)
Analyst Consensus: Buy

News

Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.

Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement Enables Amarin to Drive Additional Demand, Improve Patient Access & Educatio...

3 days ago - GlobeNewsWire

Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany

Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategy Brings groundbreaking therapy to patients in Germany with resi...

1 week ago - GlobeNewsWire

Amarin to Participate in September Investment Conferences

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming...

1 week ago - GlobeNewsWire

7 Busted Biotech Stocks Due for a Rebound

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on In...

Other symbols:ARCTARNABLUESAVATBPH
2 weeks ago - InvestorPlace

5 Stocks With 195% to 467% Upside, According to Wall Street

If these high-water price targets come to fruition, investors will be all smiles.

Other symbols:ICPTINOPLUGZGNX
2 weeks ago - The Motley Fool

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoi...

VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in REDUCE-IT patients with prior Myocardial Infarction

3 weeks ago - GlobeNewsWire

Amarin Stock Moves Higher As Vascepa Cuts Risk Of Heart Attacks

Amarin Corporation plc (NASDAQ: AMRN) announced additional data on Vascepa/Vazkepa (icosapent ethyl) in patients with prior heart attack, known as myocardial infarction (MI), at risk for major adverse c...

1 month ago - Benzinga

Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events ...

VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction

1 month ago - GlobeNewsWire

Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk ...

Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Seven Presentations Amarin-Supported Research and Analyses from International Academic Collaborators to...

1 month ago - GlobeNewsWire

Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition.

1 month ago - Zacks Investment Research

Why Amarin Is Soaring Today

The pharmaceuticals company is showing surprising resilience in the face of competition.

1 month ago - The Motley Fool

Recap: Amarin Q2 Earnings

Shares of Amarin Corp (NASDAQ:AMRN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 100.00% over the past year to $0.02, which beat th...

1 month ago - Benzinga

Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update

Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany

1 month ago - GlobeNewsWire

Best Penny Stocks to Buy? 3 to Watch In the Second Half of 2021

Looking for penny stocks to watch in the second half of 2021? Check these 3 out The post Best Penny Stocks to Buy?

Other symbols:BRQSDARE
1 month ago - PennyStocks

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.

1 month ago - Zacks Investment Research

7 Reddit Penny Stocks About to Explode

With Reddit's regular targets finally dropping, these stocks could be the next target for another crazy wave of Reddit Penny Stocks. The post 7 Reddit Penny Stocks About to Explode appeared first on Inv...

Other symbols:GOEDIAGOMQSOPKRIGWIT
2 months ago - InvestorPlace

Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021

DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management...

2 months ago - GlobeNewsWire

Why Amarin Fell Again Today

Another Vascepa generic is launched in the U.S.

3 months ago - The Motley Fool

Why Amarin Stock Is Sinking Today

The biotech's attempt to revive Vascepa's U.S. patent protection appears to be at a dead end.

3 months ago - The Motley Fool

7 Hot Penny Stocks to Watch That Are Trending Right Now

Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News a...

3 months ago - PennyStocks

Best Penny Stocks To Buy Now? 7 To Watch This Week

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Other symbols:AEZSDRRXGLBSLOTZMDWD
3 months ago - PennyStocks

Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Prese...

Studies support potentially important anti-inflammatory, protein modulation, and cell function effects of icosapent ethyl as known by the brand name VASCEPA® in much of the world and as VAZKEPA in Europ...

3 months ago - GlobeNewsWire

Why Amarin Trounced the Market on Tuesday

Investors reacted positively to a company presentation at an industry convention.

4 months ago - The Motley Fool

Amarin to Present at Two Investor Conferences in June 2021

DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Karim...

4 months ago - GlobeNewsWire

Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the...

REDUCE-IT® patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C levels

4 months ago - GlobeNewsWire